Applied Genetic Technologies (AGTC) Stock Price, News & Analysis

Company Overview

Applied Genetic Technologies Corporation, a clinical-stage biotechnology company, develops transformational genetic therapies for patients suffering from rare and debilitating diseases. Its advanced product candidates include three ophthalmology development programs across two targets, including X-linked retinitis pigmentosa, which is in the Phase 1/2 clinical trials; and achromatopsia that is in Phase 1/2 clinical trials. It is also developing an optogenetic product candidate to treat advanced retinal disease. In addition, the company has initiated one preclinical program in otology; preclinical program in dry age-related macular degeneration; and two preclinical programs in targeting central nervous system disorders, including frontotemporal dementia and amyotrophic lateral sclerosis. It has collaboration agreements with University of Florida; Bionic Sight, Inc.; and Otonomy, Inc. The company was incorporated in 1999 and is headquartered in Alachua, Florida.

Key Stats

• Today's Range: $0.39 to $0.39
• 50-Day Range: $0.37 to $0.42
• 52-Week Range: $0.23 to $2.83
• Volume: N/A
• Average Volume: 943,490 shs
• Market Capitalization: $26.62 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AGTC Stock Analysis - Frequently Asked Questions

How were Applied Genetic Technologies' earnings last quarter?

Applied Genetic Technologies Co. (NASDAQ:AGTC) released its quarterly earnings data on Tuesday, November, 9th. The biotechnology company reported ($0.40) EPS for the quarter, missing the consensus estimate of ($0.35) by $0.05.
Read the conference call transcript.

What other stocks do shareholders of Applied Genetic Technologies own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Genetic Technologies investors own include Tesla (TSLA), Meta Platforms (META), NIO (NIO), NVIDIA (NVDA), Sorrento Therapeutics (SRNE), Advanced Micro Devices (AMD) and Viking Therapeutics (VKTX).

Company Calendar

• Last Earnings: 11/09/2021
• Today: 5/10/2025
• Fiscal Year End: 6/30/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological products, except diagnostic
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AGTC
• CIK: 1273636
• Web: www.agtc.com
• Phone: (386) 462-2204
• Fax: N/A
• Employees: 83
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.46)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-68,940,000.00
• Net Margins: N/A
• Pretax Margin: -21,537.54%
• Return on Equity: -192.90%
• Return on Assets: -92.54%

Debt

• Debt-to-Equity Ratio: 0.39
• Current Ratio: 1.40
• Quick Ratio: 1.40

Sales & Book Value

• Annual Sales: $320,000.00
• Price / Sales: 83.19
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.26 per share
• Price / Book: 1.51

Miscellaneous

• Outstanding Shares: 67,632,000
• Free Float: 64,859,000
• Market Cap: $26.62 million
• Optionable: Optionable
• Beta: 1.55